Analyzing AD and allergies

July 1, 2007

An ongoing longitudinal study is investigating whether early and continued treatment of atopic dermatitis with the topical immunomodulator pimecrolimus 1 percent cream (Elidel, Novartis) can prevent future development of asthma and other allergies. The multicenter trial was launched more than three years ago and randomized 1,091 children ages 3 months to 18 months old. An analysis of the demographic features of the study population highlights the value of the cohort for investigating a number of questions about AD and allergies.